CytomX Therapeutics CTMX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's total operating expenses?
- CytomX Therapeutics (CTMX) reported total operating expenses of $29.93M in Q1 2026.
- How has CytomX Therapeutics's total operating expenses changed year-over-year?
- CytomX Therapeutics's total operating expenses increased by 5.8% year-over-year, from $28.3M to $29.93M.
- What is the long-term trend for CytomX Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), CytomX Therapeutics's total operating expenses has grown at a -10.5% compound annual growth rate (CAGR), from $153.35M to $98.57M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.